In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Insulet’s current price exceeds its PERT-weighted fair value by 18.6%, indicating potential overvaluation. Diverging valuation estimates—negative DCF but strong analyst targets—highlight model inconsistencies. Strong liquidity and profitability scores contrast with moderate growth and efficiency, suggesting mixed financial foundations amid limited downside risk.